Technology · Health & biomedicine / Therapeutics & platforms
mRNA platforms & LNP delivery
Synthetic mRNA in lipid nanoparticles (60–100 nm) turns the cell into a bioreactor — from a vaccine platform to personalised cancer immunotherapy and in-vivo protein expression.
1 · What it gives
mRNA platforms with lipid-nanoparticle (LNP) delivery are a revolutionary biopharma paradigm: synthetic messenger RNA carries the genetic instruction straight into the cytoplasm, turning the cell into a bioreactor for therapeutic proteins, antigens or personalised neoantigens. Because “naked” mRNA is unstable, LNPs of 60–100 nm encapsulate it, enabling endocytosis and endosomal escape. An LNP has four lipids: ionizable (neutral at pH 7.4, positive in the endosome), PEG-lipid, phospholipid and cholesterol. After the COVID-19 breakthrough (Comirnaty, Spikevax), the sector is scaling into cancer vaccines and replacement protein therapy.
Key directions of mRNA platforms:
- Infectious vaccines (Infectious Vaccines): COVID-19, RSV, influenza — platform re-use of the LNP shell.
- Personalised cancer vaccines (Personalised Cancer Vaccines): up to 34 neoantigens per patient (mRNA-4157).
- Self-amplifying RNA (Self-Amplifying RNA): saRNA needs lower doses (ARCT-154).
- In-vivo protein expression & in-vivo CAR (In-Vivo Protein Expression): rare-disease therapy and CAR-T without ex-vivo.
Sectoral value chain#
[DNA template] ──> [IVT transcription] ──> [mRNA purification] ──> [LNP assembly]
│
(cell-free synthesis)
│
▼
[drug product] <─── [fill/lyophilisation] <─────┘
Value chain levels#
| Level | Description | Key inputs/outputs |
|---|---|---|
| DNA Template | plasmid DNA in E. coli + linearisation | In: strains, restriction enzymes. Out: linear DNA template. |
| IVT Transcription | cell-free mRNA synthesis (T7, m1Ψ, NTPs) | In: template, T7, CleanCap. Out: raw mRNA. |
| mRNA Purification | dsRNA removal (RP-HPLC) to >98% purity | In: raw IVT product. Out: pure mRNA. |
| LNP Formulation | microfluidic self-assembly (pH 4.0) | In: mRNA, 4 lipids. Out: LNP emulsion. |
| TFF & Buffer Exchange | ethanol removal, shift to pH 7.4 | In: LNP suspension. Out: neutral suspension. |
| Aseptic Fill & QC | sterile fill, lyophilisation, release | In: suspension. Out: drug product (vial). |
Cross-cutting technologies of the sector:
- Nucleotide modification (Nucleotide Modification): N1-methylpseudouridine (m1Ψ) — 2023 Nobel — dampens innate immunity.
- Microfluidic mixing (Microfluidic Mixing): herringbone mixers give PDI <0.1 and encapsulation >90%.
- Co-transcriptional capping (Co-transcriptional Capping): CleanCap® — >95% Cap-1 in one step.
2 · What it replaces 0 · matched by industry
No graded substitution linked yet.
3 · How to implement 6 steps
- 1DNA templatePlasmid DNA (T7 promoter + poly-A 100–120 nt) is produced in E. coli and linearised with restriction enzymes.
- 2IVT synthesisSynthesis & conversionThe reactor is loaded with template, T7 polymerase, CleanCap and NTPs (UTP→m1ΨTP); 37°C, 2–4 h; DNase then removes the template.Who can do this step matched automaticallyBota Bio 恩和生物 China✓ ISO 9001 600 tons pilot scale“Protein expression is limited by multiple bottlenecks, such as transcription efficiency, translation efficiency, metabolic constraints, protein folding, and hydrolysis.”Toyobo Japan“Core technologies include polymerization, modification, processing, and biotechnology.”“2026-06-28 [BIOCATALYST LEADERSHIP: How Enzymes are Propelling India's Pharma Bio Spectrum - business - Read this story on Magzter.com — A brief mention of Aum Enzymes or Infinita …”163,050 tonnes“Uniquely equipped with the credentials for the R&D, design, and production of both high-efficiency dust filtration materials and SCR denitration catalysts, as well as for the …”
- 3mRNA purificationPurification & downstreamUltrafiltration + RP-HPLC remove dsRNA; mRNA is transferred to pH 4.0 buffer and frozen at -80°C.Who can do this step matched automaticallyEsco Aster Singapore✓ ISO 9001 5,000 L industrial scale“Adherent cell culture and downstream processing: commercialized Tide Motion bioreactor platform (MiniTide to TideXcell) with closed automated cell harvesting and single-use …”HLB Genex (ex-GenoFocus) South Koreaindustrial scale“With fungal and bacterial secretion systems, we custom produce the evolved enzyme products in large-scale fermentation and downstream processes.”Space F South Korea“2026-07-12 [Korea's next drug lab is in orbit - The Korea Herald — Space LiinTech is advancing Korea’s foray into space-based drug research with autonomous microgravity platforms …”SilicoBio South Koreaindustrial scale“SilicoBio is a privately held KAIST faculty startup (South Korea) developing precision-fermentation cell factory platforms to scale microbial foods and functional ingredients …”
- 4LNP assemblyLipids in ethanol and mRNA at pH 4.0 are mixed in a microfluidic chip; the ionizable lipid binds the mRNA.
- 5TFFTangential-flow filtration (100–300 kDa) removes ethanol and shifts the buffer to pH 7.4.
- 6Fill & lyophilisationPurification & downstreamSterile 0.22 µm filtration, aseptic filling under nitrogen; lyophilisation with sucrose/trehalose; storage at -20…-80°C.Who can do this step matched automaticallyEsco Aster Singapore✓ ISO 9001 5,000 L industrial scale“Adherent cell culture and downstream processing: commercialized Tide Motion bioreactor platform (MiniTide to TideXcell) with closed automated cell harvesting and single-use …”HLB Genex (ex-GenoFocus) South Koreaindustrial scale“With fungal and bacterial secretion systems, we custom produce the evolved enzyme products in large-scale fermentation and downstream processes.”Space F South Korea“2026-07-12 [Korea's next drug lab is in orbit - The Korea Herald — Space LiinTech is advancing Korea’s foray into space-based drug research with autonomous microgravity platforms …”SilicoBio South Koreaindustrial scale“SilicoBio is a privately held KAIST faculty startup (South Korea) developing precision-fermentation cell factory platforms to scale microbial foods and functional ingredients …”
4 · Who delivers
Matched suppliers (matched automatically)
| Brevel | Israel | Producer | active |
| Esco Aster | Singapore | Services / consulting | active |
| Unibio | Denmark | Producer | active |
| Integriculture | Japan | Equipment | active |
| Loopworm | India | Services / consulting | active |
| Fermelanta | Japan | Producer | active |
Leading companies and institutes (from the brief)
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Moderna | 🇺🇸 USA | Spikevax, mRNA-4157 (cancer vaccine) | AI codon design, proprietary lipids | Commercial |
| BioNTech | 🇩🇪 Germany | Comirnaty, BNT122 | neoantigens, BioNTainer plants | Commercial |
| CureVac | 🇩🇪 Germany | gen-2 mRNA (with GSK) | codon optimisation of unmodified RNA | Operating |
| Arcturus | 🇺🇸 USA | LUNAR®, ARCT-154 (saRNA) | saRNA (low doses), biodegradable lipids | Commercial |
| Abogen | 🇨🇳 China | AWcorna | thermostable LNPs (+2–8°C) | Operating |
| TriLink | 🇺🇸 USA | CleanCap® | co-transcriptional capping >95% | Commercial |
5 · Rules & route to market
United States
The US leads on mRNA capitalisation, patents and clinical scale-up, with mature CDMO infrastructure.
Moderna leadership, CDMO infrastructure, FDA platform guidance#
- Moderna: mRNA-4157 (V940) + Keytruda — phase III melanoma recurrence reduction.
- CDMO + LNP components: TriLink (CleanCap), Catalent, Lonza — full upstream capacity.
- FDA: platform regulatory guidance — re-use of LNP-shell safety data across candidates.
European Union
The EU is the birthplace of key nucleotide-modification and LNP discoveries, with strict ATMP regulation.
BioNTech/CureVac phenomenon, EMA ATMP regulation#
- BioNTech (Mainz): Comirnaty (with Pfizer) + onco-pipeline; modular BioNTainer plants.
- CureVac: oldest mRNA-stabilisation patent portfolio (GC optimisation, with GSK).
- EMA ATMP: strict validation of dsRNA clearance and LNP-size stability under GMP.
China
China treats mRNA as a biotech-sovereignty domain, localising the whole lipid and enzyme chain.
Walvax/Abogen, raw-material localisation, Suzhou BioBAY hub#
- Abogen/Walvax: AWcorna and domestic mRNA vaccines; LNPs stable at +2–8°C.
- Localisation: Yeasen — m1Ψ, T7 polymerase, ionizable lipids (SM-102/ALC-0315 analogues).
- BioBAY (Suzhou): China’s main mRNA cluster (hepatitis B, liver cancer, metabolic diseases).
6 · Money: tenders & grants
| Grant | Development of cell-free protein synthesis platforms for discovery and/or production of biologicals European Commission · EU | Apr 13, 2027 179 days |
| Grant | Prevention and mitigation of misuse of synthetic biology for bioterrorism purposes European Commission · EU | Nov 5, 2026 20 days |
7 · Tech stack & innovations
The stack rests on cell-free synthesis, microfluidics and deep purification.
- IVT synthesis (In Vitro Transcription):
- T7 polymerase at 37°C, Mg^2+ cofactor; yield 5–10 g RNA/L.
- full UTP→m1ΨTP replacement to bypass RIG-I/MDA5.
- Microfluidic LNP assembly (Microfluidic LNP Assembly):
- mixing lipids in ethanol with mRNA at pH 4.0; ethanol dilution triggers self-assembly.
- Deep RNA purification (Deep RNA Purification):
- RP-HPLC/HIC to remove dsRNA that drives interferon response.
Where this appears 10 sources
Appears in 10 distinct sources across 6 regions, 2022–2026.
- directory listings 2
- podcasts 1
- policy documents 4
- reports 3
Regions: Asia-Pacific · Belgium · China · Global · Singapore · Taiwan
- 2021: 0
- 2022: 11
- 2023: 33
- 2024: 33
- 2025: 11
- 2026: 22
- 2027: 0
Matched themes 10
Optimizing mRNA technology mRNA mRNA Engineering mRNA Vaccines mRNA as Therapeutic Solutions mRNA therapies mRNA vaccine development mRNA相關技術 messenger RNA 单链RNA噬菌体自组装的工程mRNA疫苗
Themes from forum programmes, policy documents and reports are mapped to technologies automatically and then reviewed; counts are distinct sources, not mentions, and are not a ranking. data sources and method → · Trending, not yet covered →